Comparative Pharmacology
Head-to-head clinical analysis: E E S versus ERY TAB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E E S versus ERY TAB.
E.E.S. vs ERY-TAB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin (E.E.S.) binds to the 50S subunit of bacterial ribosomes, inhibiting peptide chain elongation and protein synthesis. It also exhibits prokinetic effects on the gastrointestinal tract via motilin receptor agonism.
Erythromycin binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation step.
250-500 mg every 6 hours orally or 15-20 mg/kg/day IV divided every 6 hours.
250-500 mg orally every 6 hours or 333-666 mg every 8 hours. Maximum 4 g/day.
None Documented
None Documented
1.5-2 hours in adults with normal renal function; prolonged to 4-6 hours in patients with hepatic impairment; may be shorter in children.
The terminal elimination half-life of erythromycin base is approximately 1.5-2 hours in patients with normal renal function. In patients with end-stage renal disease, the half-life may be prolonged to 4-6 hours. The half-life is not significantly altered in hepatic impairment, but accumulation can occur with severe liver disease.
Primarily hepatic (biliary) excretion of unchanged drug and active metabolites; approximately 15% of an oral dose is excreted unchanged in urine. The remainder is eliminated via feces as unchanged drug and metabolites.
Erythromycin is primarily excreted in bile as active drug and metabolites, with approximately 12-15% of an administered dose excreted unchanged in urine. Fecal elimination accounts for about 30-60% of the dose, largely due to biliary excretion.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic